Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Investor Presentation (April 2026)
39 slides from Recce Pharmaceuticals's investor presentation, April 2026
Slide 1: RCE Corporate Presentation
RCE Corporate Presentation ASX:RCE | FSE:R9Q April 2026 0
Slide 2: Disclaimer
Disclaimer DISCLAIMER FUTURE MATTERS This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of not purport to contain all the information that a prospecti
Slide 3: Company Overview
Company Overview
Slide 4: Recce Pharmaceuticals – Company Overview
Recce Pharmaceuticals – Company Overview An Australian clinical-stage biotech with a United States presence, developing a New Class of Synthetic Anti-infectives with a unique mechanism of action for a broad spectrum of infections including serious/life-threatening indications. • Publicly-traded on t
Slide 5: Board and Management Structure
Board and Management Structure Dr John Prendergast – Chairman BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) Michele Dilizia – Executive Director & Chief Scientific Officer BSc (Med Sc i), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM US-based, current Chairman and Co-founder of Palatin Technologies,
Slide 6: Company Overview
Company Overview Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives Capital Structure – April 2026 RCE Share Price and Volume Chart – 12 Months (price shown in AUD) ASX & FSE Code RCE, R9Q 1,200,000 $0.80 $0.70 Share Price AUD $0.47 1,00
Slide 7: The Advantages of a New Class of Antibiotics
The Advantages of a New Class of Antibiotics Recce is on-track to be the only global clinical stage company whose drug is shown to be efficacious against the full suite of ESKAPE pathogens Unprecedented, broad-spectrum activity against Gram-positive and Gram-negative bacteria Universal Mechanism of
Slide 8: Large Addressable Market
Large Addressable Market The global diabetic foot infection (DFI) market • The DFI treatment market is estimated to be worth ~US$5.2 billion1 US$5.2B • Initially targeting Indonesian market valued at ~US$189 million where DFI impacts 11% of the population 2 Est. global DFI treatment • Significant ne
Slide 9: Program Pipeline for 2026
Program Pipeline for 2026 Various indications and upcoming inflection points • Approval received from the Indonesian Drug and Food Regulation Authority, Badan POM, to initiate its Registrational Phase 3 clinical trial in Indonesia • ABSSSI includes postoperative infection, wound infections and diabe
Slide 10: RECCE 327 Synthetic Anti-Infective
RECCE® 327 Synthetic Anti-Infective 9
Slide 11: Independent Study Undertaken on RECCE MoA
Independent Study Undertaken on RECCE® 327 MoA1 Linnaeus Biosciences MoA studies of R327 Novel mechanism which targets rapid access to and shut down of bacterial energy production (ATP), which results in bacterial death of both active and resting bacteria. Stage 2 Stage 4 Stage 1 Stage 3 R327 target
Slide 12: RECCE 327 Maintains Activity
RECCE® 327 Maintains Activity Amoxicillin loses activity after a maximum of 8 repeats; RECCE ® 327 remains active for more than 25 repeats 25 repeats at time of discovery was sufficient for PCT patent applications, with no sign of resistance. Number of repeats before displaying loss of antibiotic ac
Slide 13: Bactericidal Effect of RECCE on ESKAPE Pathogens
Bactericidal Effect of RECCE® 327 on ESKAPE Pathogens E. faecium ATCC 19434 S. aureus ATCC 29213 K. pneumoniae ATCC 43816 A. baumannii ATCC 17978 P. aeruginosa ATCC 27853 Enterobacter cloacae ATCC 13047 • Average time-kill curves of R327 at various concentrations against strains of ESKAPE pathogens
Slide 14: RECCE 327 Topical Gel
Nn N ioe) © LU O O LU o~ ® O @ 2 o -
Slide 15: RECCE Topical Gel
RECCE® 327 Topical Gel First-Line Local Treatment for Infected Wounds No Pathogen Identification Required Rapid Clinical Response • Applied directly to infected tissue • Clinical and TGA Special Access Scheme use demonstrates visible reduction in • Localised antimicrobial action at the site of infec
Slide 16: DFIs: Addressing a High-Burden Infection Setting
DFIs: Addressing a High-Burden Infection Setting DFIs are complex infection Local infection RECCE® 327G was designed environments management in DFIs with DFI complexity in mind • Compromised blood flow, impaired • Direct delivery of anti-infective • Designed for direct application immune response an
Slide 17: Regulatory Acceleration & ASEAN Commercial Entry
Regulatory Acceleration & ASEAN Commercial Entry High-Impact • ~20M people living with diabetes Market • In Indonesia, DFIs are severe in 67.1% of hospitalised cases and result in amputation in 46.9% of patients1. • In-hospital treatment costs averaging IDR 64.95 million (USD ~$4,100) per patient1.
Slide 18: Registrational Phase 3 Clinical Trial - Indonesia
Registrational Phase 3 Clinical Trial - Indonesia Study Title: Phase 3, Double-blind, Placebo-Controlled Study of R327 Topical Gel for the Treatment of Diabetic Foot Ulcer Infections Population Up to 310 participants will Intervention be enrolled who present with a mild diabetic foot infection. Part
Slide 19: Registrational Phase 3 Clinical Trial - Indonesia
Registrational Phase 3 Clinical Trial - Indonesia Phase 3, Double-blind, Placebo-Controlled Study of R327 Topical Gel for the Treatment of Diabetic Foot Infections Timeline 2026 2027 Phase 3 Interim Data Readout - 155 patients R327 Topical Diabetic Foot Ulcer Infection GEL Indo trial data INDONESIA/
Slide 20: Topical Clinical Programs – Previously Completed
Topical Clinical Programs – Previously Completed • Interim data results released – primary endpoints achieved Phase I/II • Patients supported by in-home (out-patient) nurses trained in Clinical Trial R327 treatment protocols Diabetic Foot • Study across South Western Sydney health district – one of
Slide 21: Phase II ABSSSI Clinical Trial
Phase II ABSSSI Clinical Trial Achieved all Endpoints Successful clinical response • This Phase II study achieved all primary and secondary endpoints as an open-label clinical trial evaluating the safety and tolerability, efficacy, and plasma pharmacokinetics of R327G when applied directly to the in
Slide 22: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 0 Day 1 Day 30 Day 0 – Recce treatment Day 0 – Recce treatment Day 1 – Recce treatment Day 30 – Recce treatment Pre-treatment infection First Recce gel applied Post treatment Post treatment • Patient A unresponsive to 4x daily Cepha
Slide 23: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 7 Day 10 Day 14 Day 0 – Recce treatment Day 7 – Recce treatment Day 10 – Recce treatment Day 14 – Recce treatment Significant bacterial infection Wound drying up Post treatment Wound improved, well tolerated • Pre-treatment of R327G
Slide 24: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 7 Day 14 Day 21 Day 0 – Pre-treatment wound swab Day 7 – Recce treatment Day 14 – Recce treatment Day 21 – Recce treatment • Pre-treatment wound swab on Day 0 showed a growing culture ✓ Day 21 post-treatment, the wound had of both G
Slide 25: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 3 Day 7 Significant bacterial infection Redness and swelling Day 0 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment • Pre-treatment of R327G showed significant bacterial infection, ✓ Day 7 post-treatment showed wound
Slide 26: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 3 Day 7 Day 0 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment • Pre-treatment (Day 0) X-rays showed infection deep within the ✓ Day 7 post R327G treatment showed wound underlying bone, tissue and around the nail, wit
Slide 27: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 5 Significant bacterial infection Day 0 – Pre-treatment Day 5 – Recce treatment • Significant bacterial infection – septic ankle arthritis, peri- ✓ The discharge has cleared, and with no signs Left femoral prosthetic joint infection
Slide 28: RECCE 327 Clinical Programs
RECCE® 327 Clinical Programs 27
Slide 29: R327 Faster Acting Than Existing Antibiotics
R327 Faster Acting Than Existing Antibiotics No Prolonged Exposure Needed R327 is faster-acting against bacteria than other antibiotics – works quickly, without prolonged cellular exposure times required of other antibiotics (extended exposures commonly associated with systemic toxicity). R327 desig
Slide 30: RECCE Summary Results – Phase I – Complete
RECCE® 327 Summary Results – Phase I – Complete Double-blind, Placebo-controlled, Single Ascending-dose, Safety and Pharmacokinetic Study in Healthy Participants ✓ Safe and well tolerated at doses up to 6,000mg given as a 1-hour intravenous infusion; ✓ No Serious Adverse Events; – All AE’s mild or m
Slide 31: RECCE Concentrates Safely in the Urine
RECCE® 327 Concentrates Safely in the Urine Concentration of R327 Ratio Urine/Plasma in Urine Compared to Plasma 16x 17x 14x 9x In over 60 21x healthy subjects 16x – R327 primary route of elimination appears to be through – Opportunities for therapeutic in array of UTIs (uncomplicated the kidney to
Slide 32: RECCE Kills Quickly in the Urine
RECCE® 327 Kills Quickly in the Urine E. coli ATCC 25922 Treated with RECCE® 327 in Urine • R327 in the presence of human urine was able to have 10.00 a fast (near minutes) effect against E. coli and irreversible 9.00 Viable Bacteria (log CFU/ml) • Bacteria could not be revived post-treatment 8.00 •
Slide 33: Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial UTIs are responsible for about 30% of all sepsis infections, defined as ‘Urosepsis’ Clinical Trial Complete R327 has achieved multiple ‘fast infusion’ time stamps in line with intended future Assessment Assessing R327 at faster administration ra
Slide 34: Intellectual Property & Manufacturing
Intellectual Property & Manufacturing 33
Slide 35: Robust Worldwide Intellectual Property Portfolio
Robust Worldwide Intellectual Property Portfolio Recce’s patent portfolio contains over 40 patents and patent applications in the world’s major markets. Patent Patent Patent Patent Filed Expiry Expiry Expiry Expiry Family 1 Family 2 Family 3 Family 4 Australia ✓ 2028 ✓ 2037 ✓ 2037 ✓ 2041 Family 1 gr
Slide 36: Manufacturing & Scalability
Manufacturing & Scalability Manufacturing facility in Sydney’s Macquarie Park • Raw materials plentiful and cheap – few $/Kg • No expensive waste – 99.9% product yield • Automated manufacture process – completing 5,000 doses a week under GMP • This in-house pilot facility provides clear benefits in
Slide 37: RECCE – Global Recognition
RECCE® 327 – Global Recognition R327 added to World Health Organization’s List of Antibacterial Products in Clinical Development • Global recognition by the World Health Organization (WHO) – inclusion underscores significance of R327 in combating antimicrobial resistance. • Unique Mechanism of Actio
Slide 38: US Department of Defense
US Department of Defense U.S. Department of Defense CRADA with the U.S. CRADA with the U.S. Army Congressionally Directed Army Research Institute Institute of Surgical Medical Research Program of Infectious Diseases Research (USAISR) (CDMRP) Project: A Novel, Synthetic Anti-infective Project: Core A
Slide 39: Thank you
Thank you @0@ recce.com.au
Recce Pharmaceuticals — Investor Presentation (April 2026) on 6ix